What are the DORIS (Definition of Remission In Systemic Lupus Erythematosus) criteria for lupus remission?

DORIS Score for Lupus Remission

The DORIS (Definition of Remission in SLE) criteria define remission as: clinical SLEDAI-2K = 0, Physician Global Assessment (PGA) < 0.5 (on 0-3 scale), prednisone ≤ 5 mg/day, with stable antimalarials, immunosuppressives, and biologics allowed. 1

Core Components of DORIS Remission

The 2021 DORIS definition represents the international consensus standard for defining remission in lupus 1. The criteria require all of the following:

• Clinical SLEDAI-2K = 0 (excludes serological items like anti-dsDNA and complement levels)
• Physician Global Assessment < 0.5 on a 0-3 scale
• Prednisone ≤ 5 mg/day (or equivalent glucocorticoid dose)
• Stable maintenance therapy with antimalarials, immunosuppressives, and/or biologics permitted

Key Distinctions: On-Therapy vs Off-Therapy Remission

The DORIS framework distinguishes between two remission states 2:

Remission On-Therapy:

• Allows maintenance antimalarials (hydroxychloroquine)
• Permits low-dose prednisone (≤ 5 mg/day)
• Allows stable immunosuppressives (methotrexate, azathioprine, mycophenolate)
• Permits maintenance biologics (belimumab, rituximab)

Remission Off-Therapy:

• Only maintenance antimalarials allowed
• No other immunosuppressive or biologic therapy
• This is rarely achieved in clinical practice 3, 4

Serological Activity Considerations

A critical nuance: DORIS remission can be achieved with or without serological activity 2. This means patients can meet remission criteria even with:

• Positive anti-dsDNA antibodies
• Low complement (C3/C4) levels

The clinical SLEDAI-2K excludes these serological markers, focusing purely on clinical manifestations. Studies show that definitions allowing serological activity are more frequently attained while still protecting against damage accrual 4.

Clinical Significance and Outcomes

Achieving DORIS remission substantially reduces morbidity and mortality 5, 4:

• Damage accrual reduction: Odds ratios of 0.49-0.75 for organ damage progression compared to non-remission 5
• Flare prevention: Sustained remission significantly reduces disease flares 4
• Quality of life: Improved patient-reported outcomes and functional status 6

The protective effect is duration-dependent—sustained remission (spending ≥50% of time in remission) provides greater protection than intermittent achievement 4.

Practical Attainability

Real-world data reveals important feasibility considerations 3, 4:

• DORIS on-therapy remission: Achieved in 10.5-17.8% of patients at any given timepoint in clinical trials
• DORIS off-therapy remission: Achieved in ≤0.9% of patients (rarely attainable)
• Sustained remission: Even less frequently achieved but most protective

The most commonly attained definition in practice is DORIS on-therapy allowing serological activity 3.

DORIS vs LLDAS (Lupus Low Disease Activity State)

LLDAS is more attainable than DORIS remission but provides similar protection against damage 4, 7:

• LLDAS achieved in 40.8% vs DORIS remission in 17.4% of patients 7
• Both states show similar molecular pathway normalization 7
• LLDAS represents an acceptable alternative target when remission cannot be achieved 8

However, remission remains the primary treatment goal per current guidelines 8, 9, 10, with LLDAS serving as an acceptable intermediate target, particularly in established disease.

Implementation in Clinical Practice

Physician judgment shows substantial agreement (81.2%) with DORIS criteria 11, with Cohen's kappa of 0.62. Discordances mainly occur when:

• Physicians classify patients with mild ongoing activity (cSLEDAI > 0) as in remission
• PGA scores slightly exceed 0.5 despite minimal clinical activity
• Prednisone doses slightly exceed 5 mg/day in otherwise quiescent disease

The standardized DORIS definition should be used over subjective physician judgment to ensure consistent treat-to-target strategies 11.

Monitoring Frequency

For patients in remission 12:

• Assessments every 6-12 months when no activity, damage, or comorbidity present
• Disease activity measurement with validated indices at each visit
• Annual damage assessment using SDI (Systemic Lupus International Collaborating Clinics/ACR Damage Index)

Treatment Implications

Achieving and maintaining remission requires 8, 9, 10:

• Universal hydroxychloroquine use (unless contraindicated)
• Glucocorticoid minimization to < 7.5 mg/day, ideally ≤ 5 mg/day
• Early introduction of immunosuppressives to facilitate steroid tapering
• Addition of biologics (belimumab) for persistently active disease
• Regular monitoring and treatment adjustment every 3 months until target achieved

Critical caveat: Gradual glucocorticoid tapering in sustained remission can be achieved safely 5, but antimalarial discontinuation significantly increases flare risk and should be avoided 5.